Boston Scientific Corporation (NYSE:BSX) Short Interest Update

Boston Scientific Corporation (NYSE:BSX) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 28,281,105 shares, a growth of 20.8% from the January 15th total of 23,415,429 shares. Based on an average daily volume of 14,359,024 shares, the short-interest ratio is presently 2.0 days. Currently, 1.9% of the company’s stock are sold short. Currently, 1.9% of the company’s stock are sold short. Based on an average daily volume of 14,359,024 shares, the short-interest ratio is presently 2.0 days.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BSX. Barclays cut their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. Robert W. Baird reduced their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Citigroup dropped their price target on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. JPMorgan Chase & Co. dropped their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $109.30.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares during the last quarter. State Street Corp lifted its position in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares during the period. Capital World Investors grew its holdings in shares of Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Finally, Norges Bank purchased a new position in Boston Scientific in the 4th quarter worth about $2,199,395,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.7%

BSX stock traded up $1.24 during midday trading on Tuesday, hitting $75.97. The stock had a trading volume of 8,158,053 shares, compared to its average volume of 17,228,656. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The firm has a market cap of $112.62 billion, a price-to-earnings ratio of 39.18, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The business has a 50-day moving average of $90.56 and a two-hundred day moving average of $97.35. Boston Scientific has a 52-week low of $72.69 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same period last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.